The effect of social media in the healthcare industry
Written by Burton Paul
Social media has probably become one of the most important forms of communication and interaction to date. With over 750 million active users on Facebook and over 200 million Tweeters worldwide, social media has an enormous global audience.
To date, social media is an area that pharmaceutical and healthcare companies have hesitated getting heavily involved in, instead watching their rivals, waiting to see who makes the first move. Whilst conservative behaviour is certainly smart in an industry so regulated, companies are still missing a trick by overlooking the benefits of social media. Instead of hesitating, this could be an opportunity to set a trend and gain a lead in a powerful brand movement tool.
Social media has a number of advantages and can bring a huge amount of value to a company, from building trust, to humanising the company, to engaging with consumers, responding quickly to issues and providing low-cost communication. It also has an almost instant response time with a global effect. All these are benefits that the majority of companies are not utilising to their full effect.
However, before jumping into the pool of social media, it is important to know the heart of your brand, product or therapy area. The surge in the popularity of social media increasingly puts power into the hands of the consumer, making it more important than ever for companies to understand the core values affecting the brand or product, as well as the therapy area these brands live in and the challenges they are facing. If you don’t, your frailties could be very quickly exposed.
Although social media is a great tool, guiding principles should be established to ensure strict adherence to regulatory restrictions and requirements. These guiding principles need to be set from the beginning, with input from legal (and potentially quality assurance) department. Because one of the most important ways of humanising the company is by allowing employees to connect, it is imperative they understand what rules to stick by and appreciate that they represent the company as well. Full training should be provided to employees in this area.
At the end of the day, timing is extremely important. Even though a product may not be launched for some time, there is no stopping a pharmaceutical company from creating something through social media that does not reflect the product itself, but instead focuses on linking the consumer to the pharmaceutical company. This will start to build the connection in the consumer’s mind, so when the product launches, there is an established emotional connection.
Depending on whether the product or brand is a prescription or over the counter drug, the strategy will have a different focus, as one is greatly more restricted than the other. This comes back to the simple thought that just because you cannot speak about the drug itself, doesn’t mean you cannot speak at all. When you speak, depending on how and what you say, people will not just listen, but also potentially participate.
About the author
Burton Paul has over 15 years experience in managing projects and clients across a wide range of sectors including FMCG and pharmaceuticals. His work includes brand delivery for some of the biggest names in the sector; most notably Adcock Ingram, Arrow Generics, BMS, Cephalon, Eusa Pharma, GE Healthcare, King Pharmaceuticals, Mylan, Peptech, SSL (Reckitt Benckiser) and Synpart. His new role see’s him as Client Director at leading entrepreneurial and creative branding agency 1HQ - www.1hq.co.uk.
Our magazine is now available on the iPad. Click here to download it.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”